SOURCE: Trxade Group, Inc.

September 30, 2014 10:31 ET

Trxade Group, Inc. Advances to Direct Sales Model Utilizing Existing Pharmaceutical Network

TAMPA, FL--(Marketwired - Sep 30, 2014) - Trxade Group, Inc. (OTCQB: TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced the launch of our new direct sales model through our wholly owned subsidiary, Westminster Pharmaceuticals, LLC. Westminster Pharmaceuticals will usher in an entirely new profit model for the company, allowing us direct market distribution for Private Label of Pharmaceuticals, pre-formulation, formulation development, scale-up, technical transfer of Tablets, Semi Solids, Oral Liquids, Topical applications and Non-sterile Liquids for Abbreviated New Drug Application/New Drug Application (ANDA/NDA) filing with Quality by Design (QBD) concept. In connection with this exciting new profit center, Dr. Ramesh Kenchappa, M.S.(Pharma), Ph.D., is joining the Company as Chief Scientific Officer. Dr. Ramesh will manage the Research & Development team at Westminster Pharmaceuticals.

"From the very start our business plan called for the establishment of a large network between existing pharmacies which would in turn allow for the direct distribution of numerous private label products through our direct contract pharmaceutical manufacturing relationships. We believe this will lead to a significant growth in our margins and revenues and provide a significant if not dominant contribution to our bottom line," said Suren Ajjarapu, Trxade Chairman and CEO. "This is the sweet spot for growth and the addition of Dr. Ramesh Kenchappa ensures we have the experience to begin that process. We are excited to have Dr. Ramesh join us."

Dr. Ramesh holds a Ph.D. in pharmaceutical sciences with over 20 years of formulation development & management experience. He has worked in various senior management level positions in reputable pharmaceutical companies. Prior to this he was Chief Scientific Officer (CSO) & Executive VP of Remedex Pharmaceuticals. He also worked as the Senior Director at Sancilio and Company, Manager for Qualitest Pharmaceuticals, and Principal Scientist for Azopharma, Senior Scientist for Watson Pharmaceuticals, Pharmascience and Astra Zeneca. Dr. Ramesh's areas of research include control release technology, enhanced bioavailability of poorly soluble drugs & Bilayer tablet technology. He is specialized in developing solid, liquid, semisolid, capsule, soft gel formulation & topical applications for NDA & ANDA submissions. He is also specialized in technology transfers, site transfers, trouble shooting, process development and process improvement of pharmaceutical dosage forms. Dr. Ramesh was evaluator for several pharmaceutical Doctorate programs from reputed universities and served as editorial board in several pharmaceutical journals. He gained his Ph.D. in pharmaceutical sciences from Andra University, India. He is author of a number of research articles published in respected journals. 

"I'm thrilled to be joining the Trxade Team for this exciting new company division launch. My entire career has been spent in the Pharmaceutical industry and I look forward to continuing that tradition by providing 'best of breed' Private label distribution services to Trxade's current and future customers," Dr. Ramesh said.

Suren Ajjarapu, Trxade Chairman and CEO, stated: "We are very excited to welcome Dr. Ramesh to our team at Trxade. Not only will he bring a tighter focus on customer relationship quality to our scientific team/distribution team, but also be a great role model for our employees and vendors who come into contact with him."

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. is a web-based market platform that enables trade among healthcare buyers and sellers of pharmaceuticals, accessories and services. Please visit us at http://www.trxadegroup.com/

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. Except as may be required by applicable law, we assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Contact Information